Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes
The present invention relates to the field of medicine and provides pharmaceutical compositions comprising one or more of the following isolated amino acid sequences comprising or, alternatively, consisting of, SEQ. ID No.: 3, and/or SEQ. ID No.: 1, and/or SEQ ID No.: 2, kits and conjugates comprising one or more of the above mentioned amino acid sequences. In addition, the present invention relates to the use of the pharmaceutical compositions, kits and conjugates of the present invention as a medicament, in particular in the treatment of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent. The present invention also provides a device for selective binding and separation of at least one component from an aqueous solution wherein the device comprises one or more of the above mentioned amino acid sequences.
1. A pharmaceutical composition comprising one or more isolated amino acid sequences consisting of a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 1, SEQ ID NO: 2, and derivatives thereof, wherein said derivatives are a peptide consisting of SEQ ID NO: 3, SEQ ID NO: 1, or SEQ ID NO: 2 with (i) one modification of a C-terminal end selected from C-amidation and C-esterification and/or one modification of an N-terminal end selected from N-acylation and N-alkylation, (ii) replacement of one or more L-amino acids with corresponding D-amino acids, (iii) conjugation with polyethylene glycol or albumin, or (iv) combinations of any of (i), (ii), or (iii).
2. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a solid composition or a liquid composition.
3. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition further comprises pharmaceutically acceptable carriers, pharmaceutically acceptable salts, adjuvants, excipients, or combinations thereof.
4. A conjugate comprising one or more isolated amino acid sequences comprising an 11-mer amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 1, SEQ ID NO: 2, and derivatives thereof, wherein said derivatives are SEQ ID NO: 3, SEQ ID NO: 1, or SEQ ID NO: 2 with (i) one modification of a C-terminal end selected from C-amidation and C-esterification and/or one modification of an N-terminal end selected from N-acylation and N-alkylation, (ii) replacement of one or more L-amino acids with corresponding D-amino acids, or (iii) combinations of (i) or (ii).
5. The conjugate according to claim 4 , wherein the one or more isolated amino acid sequences is conjugated to a polymer.
6. The conjugate according to claim 5 , wherein the polymer is a soluble polymer or an insoluble polymer.
7. A kit-of-parts comprising one or more isolated amino acid sequences consisting of a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 1, SEQ ID NO: 2, and derivatives thereof and an antibiotic, wherein said derivatives are a peptide consisting of SEQ ID NO: 3, SEQ ID NO: 1, or SEQ ID NO: 2 with (i) one modification of a C-terminal end selected from C-amidation and C-esterification and/or one modification of an N-terminal end selected from N-acylation and N-alkylation, (ii) replacement of one or more L-amino acids with corresponding D-amino acids, (iii) conjugation with polyethylene glycol or albumin, or (iv) combinations of any of (i), (ii), or (iii).
8. The kit-of-parts according to claim 7 , wherein the antibiotic is Imipenem.
9. The kit-of-parts according to claim 7 , wherein said kit-of-parts further comprises a dehydropeptidase inhibitor or a beta-lactamase inhibitor.
10. The kit-of-parts according to claim 9 , wherein the dehydropeptidase inhibitor or beta-lactamase inhibitor is Cilastatin.
11. The kit-of-parts according to claim 9 , wherein the antibiotic is Imipenem and the dehydropeptidase inhibitor or beta-lactamase inhibitor is Cilastatin.